Link to pre-proof of our review on frailty and frailty syndromes in people with haemophilia doi.org/10.1016/j.jt... Hope to raise awareness to improve screening and current clinical pathways. Much more work needed including for women and for other bleeding disorders!

This #WorldHemophiliaDay, we’re spotlighting the overlooked history of women and hemophilia. Experts Paula James and Megan Chaigneau join the ISTH Pulse Podcast to share insights from their powerful narrative review in @jthjournal.bsky.social 🎧Listen: bit.ly/3Ept29w #WHD2025

🎉 Happy #WorldHemophiliaDay! This year’s theme, “Access for all: Women and girls bleed too,” is a call to action and a reminder that equity in care starts with awareness. Here’s to building a more inclusive future, together. 💪 #WHD2025 #WeBleedToo #ISTH2025

Comprehensive review of gene therapy in #hemophilia accepted for publication by Molecular Therapy. The pre-proof is on line at tinyurl.com/3sb4nuex

Important paper: In patients with cancer and venous thrombosis, extended anticoagulation with low dose Apixaban is as good as full dose Apixaban in preventing thrombosis recurrence and is associated with less bleeding. tinyurl.com/yyfuan35

In an unprecedented move, the US National Institutes of Health has begun mass terminations of research grants that fund active scientific projects because they no longer meet “agency priorities”. https://go.nature.com/4bpG2It

Great to share our new paper in @jthjournal.bsky.social - Fibrin film on clots is increased by hematocrit but reduced by inflammation: implications for platelets and fibrinolysis www.jthjournal.org/article/S153... @universityofleeds.bsky.social #fibrinogen #thrombosis #hemostasis #inflammation

Should patients seen in #SDEC #AmbulatoryCare receive #VTE prophylaxis? Our data #WarwickMedSchool @susie-shapiro.bsky.social show VTE rate in SDEC as high as hospitalised patients. Ability to ambulate does NOT equal reduced VTE risk. @ukhahsoc.bsky.social www.sciencedirect.com/science/arti...

We report 0.9% VTE within 90 days of hospital led acute ambulatory care attendance; similar to traditional medical inpatient care without thromprophylaxis. Further VTE research needed in this rapidly expanding area of medicine#VTE#SDEC @danlasserson.bsky.social www.sciencedirect.com/science/arti...

Pleased to share this perspective on andexanet alfa, now published in @rpth.bsky.social #openaccess🔓 rpthjournal.org/article/S2475-… I cover blinding, surrogate endpoints, clinical outcomes and thrombosis. A brief 🧵

This is your chance to shape the field of #thrombosis and #hemostasis. Apply for editorial positions at @isth-official.bsky.social journals @RPTH.bsky.social - Assoc. Editor (2x) @JTHjournal.bsky.social - Early Career Assoc. Editor (1x) Deadline is Jan 30! Apply here 👇 https://buff.ly/3BRloDM

🩸 Nonneutralizing antibodies (NNAs) in moderate #hemophilia A & B were found in 13% of Nordic patients, linked to >150 exposure days and worse joint outcomes (higher joint health scores, more surgeries). Further research is key to understanding these impacts! @ragnhijm https://buff.ly/3OWH58e

Until now, (non-approved) emicizumab use in acquired hemophilia A was all about reduction in bleeds and improved convenience for patients and medical staff. Now the German group showed at #ASH2024 that it results in improved survival. Not randomised but impressive.

Systematic review and meta-analysis of all the AAV gene therapy trials in #hemophilia A and B. Remarkably, 395 patients have had gene therapy for hemophilia during the clinical trials already. tinyurl.com/47vrua3v

#Ash24 #hemesky Very large datasets suggest factor 12 haploinsufficiency substantially reduce venous #thrombosis. Suggest intravascular pathological clot formation is molecularly different than extra vascular hemostatic clot formation?

Fascinating study from administrative data showing 20% lower risk of #VTE with GLP-1 receptor agonist use in diabetes in a large population sample. Association was similar even in people with normal BMI. #ASH24

90% of women with #vonWillebrandDisease in our pilot study said their periods are heavy, impacting physical and general daily activities. We want to help change this. Can you help us? If you live with von Willebrand’s, find out more about our survey here: loom.ly/yIk8Rwg #HemeSky #MedSky

Paper in this week's NEJM shows that in patients with atrial fibrillation and stable coronary artery disease, edoxaban monotherapy is superior to the combination of edoxaban plus an antiplatelet drug. Major difference was in bleeding rather than reduction in ischaemic events.

Really proud of our physio Steph! Thank you to UK Haemophilia Society, Ben and others for this lovely recognition of her care and support! @ouhospitals.bsky.social www.ouh.nhs.uk/news/article...

Tons of NEW DATA about andexanet, presented as part of FDA hearing last week. If you couldn’t make it through the short 6h meeting, GOOD NEWS, I’ve watched it and highlighted the important points. A🧵

⌛The countdown is on! The ISTH 2025 abstract submission portal opens Nov 29. Join us for ##ISTH2025 in Washington DC & plan to showcase your research on the global stage. 🗓️Abstract submission deadline is Jan. 15! 💡http://isth2025.org/abstracts ##HemeSky

The World Federation of #Hemophilia 2023 Annual Global Survey was published today. These are the best international data on inherited bleeding disorders. Europe and the Americas have 28% of the world population and use 79% of the world's FVIII concentrate. tinyurl.com/4muevre6

Wow! PETS has closed after recruiting over 11,000 because the research Q as to the benefit of stockings in low risk surgical pts has been answered. We wont know the answer until completed analysis & then publication in 2025 The largest ever trial on stocking!

Really exciting to have gene therapy for haemophilia B as an option in the UK. It needed us to establish new models of care to ensure access and safety. UK guidance for implementation of gene therapy just published: doi.org/10.1111/hae....